5435932025-10-012025-12-315435932025-12-315435932025-04-012025-12-315435932025-10-012025-12-31in-capmkt:OtherExpenses1Member5435932025-10-012025-12-31in-capmkt:OtherExpenses2Member5435932025-04-012025-12-31in-capmkt:OtherExpenses1Member5435932025-04-012025-12-31in-capmkt:OtherExpenses2Member5435932025-10-012025-12-31in-capmkt:ReportableSegments1Member5435932025-10-012025-12-31in-capmkt:ReportableSegments2Member5435932025-10-012025-12-31in-capmkt:ReportableSegments3Member5435932025-04-012025-12-31in-capmkt:ReportableSegments1Member5435932025-04-012025-12-31in-capmkt:ReportableSegments2Member5435932025-04-012025-12-31in-capmkt:ReportableSegments3Member5435932025-10-012025-12-31in-capmkt:ReportableSegments1Member5435932025-10-012025-12-31in-capmkt:ReportableSegments2Member5435932025-10-012025-12-31in-capmkt:ReportableSegments3Member5435932025-04-012025-12-31in-capmkt:ReportableSegments1Member5435932025-04-012025-12-31in-capmkt:ReportableSegments2Member5435932025-04-012025-12-31in-capmkt:ReportableSegments3Member5435932025-10-012025-12-31in-capmkt:ReportableSegments1Member5435932025-12-31in-capmkt:ReportableSegments1Member5435932025-10-012025-12-31in-capmkt:ReportableSegments2Member5435932025-12-31in-capmkt:ReportableSegments2Member5435932025-10-012025-12-31in-capmkt:ReportableSegments3Member5435932025-12-31in-capmkt:ReportableSegments3Member5435932025-10-012025-12-31in-capmkt:ReportableSegments1Member5435932025-12-31in-capmkt:ReportableSegments1Member5435932025-10-012025-12-31in-capmkt:ReportableSegments2Member5435932025-12-31in-capmkt:ReportableSegments2Member5435932025-10-012025-12-31in-capmkt:ReportableSegments3Member5435932025-12-31in-capmkt:ReportableSegments3Member5435932025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15435932025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15435932025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15435932025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares543593DBOLNAINE0I3401014Dhampur Bio Organics LimitedMain BoardEquity2025-04-012026-03-312026-01-212026-01-17INRCroresQuarterlyThird quarterMulti segment2026-01-2120:16:002026-01-2121:00:00Not applicable2025-10-012025-12-31UnauditedConsolidated751260000089500000760210000059733000005100000-2615200000295900000106000000153100000342710000073453000002568000000256800000-100000879000008780000001690000000000169000000-1300000015600000016900000001560000000663900000102.562.55002.562.55Notes to Consolidated Financial Results <BR> i) These unaudited consolidated financial results which are published in accordance with Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations’) have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 21, 2026. These unaudited standalone financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards ("Ind-AS") prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. <BR> ii) These unaudited consolidated financial results have been subjected to a limited review by the statutory auditors of the Parent Company. The statutory auditors have expressed an unmodified conclusion in the review report for the quarter and nine months ended December 31, 2025. <BR> iii) The Parent Company has two wholly owned subsidiaries, Sonitron Bio Organics Private Limited & Dhampur International Pte. Limited as on December 31, 2025 <BR> iv) Pursuant to the resolution passed by the shareholders of the Parent Company dated May 4, 2025 via Postal Ballot wherein DBO Employee Stock Option Scheme 2025 was approved, during the quarter ended September 30, 2025, the Parent Company granted 357881 stock options convertibles into equal number of equity shares of the Parent Company of face value of Rs. 10/- each, as approved by the Nomination and Remuneration Committee (NRC) of the Parent Company, to the eligible employees of the Parent Company, through Trust route, under the DBO Employee Stock Option Scheme 2025. <BR> v) Other income for the quarter and nine months ended December 31, 2025 includes insurance claims of Rs. 8.64 Crore and Rs. 17.92 Crore respectively, equivalent to the loss / expenditure incurred due to break downs and accidents during the period respectively, which are accounted and provided for as per consistent accounting policy followed by the Parent Company. <BR> vi) The Parent Company has granted interest free loan to the DBO Employee Welfare Trust (Trust) amounting to Rs. 500,00,000 /- (Rupees Five Crore only) and the Trust has acquired 5,84,000 shares from the market at an average price of Rs. 84.92 per share. Acquisition cost of shares held by the Trust is presented as reduction in ‘Other Equity’. Share based payment expense for the quarter and nine months ended December 31, 2025 is Rs. 0.10 crore and Rs. 0.17 crore respectively. <BR> vii) Pursuant to the implementation of the New Labour Codes with effect from November 21, 2025 (the supporting Rules are yet to be notified), the Parent Company has reassessed its employee benefit obligations and recognised defined benefit obligations as per actuarial valuation as at December 31, 2025. The Parent Company is in the process of evaluating other possible impacts, if any. However, management is of the view that impact, if any, is unlikely to be material. <BR> viii) Sugar being a seasonal industry, the performance of the quarter may not be representative of the annual performance of the Company. <BR> ix) Figures for the previous corresponding periods have been regrouped, wherever considered necessary. <BR> x) "The consolidated unaudited financial results are available on the website of the Company (www.Dhampur.com). The specified items of the standalone unaudited financial results of the Company are given below:" <BR> Particulars Quarter Ended Nine Months ended Year Ended <BR> 31-Dec-25 30-Sep-25 31-Dec-24 31-Dec-25 31-Dec-24 31-Mar-25 <BR> (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <BR> Total Income 714.21 806.58 741.08 2,343.69 2,014.54 2,718.11 <BR> Profit/ (Loss) before tax 21.49 (22.94) (9.61) (31.03) (42.43) 17.84 <BR> Profit/ (Loss) after tax 13.87 (15.53) (6.21) (21.03) (27.56) 12.09 <BR> <BR> (* Diluted EPS is anti-dilutive for nine months ended 31 December 2025 and quarter ended 30 September 2025.)2025-04-012025-12-31UnauditedConsolidated235982000002401000002383830000072291000004023000005030100000814300000465100000441400000976280000024145100000-3068000000-3068000004800000-100700000-959000000-2109000000000-210900000-3800000-214700000-2109000000-214700000066390000010-3.19-3.1900-3.19-3.19Excise duty on sale of goods2649200000Other Expenses777900000Excise duty on sale of goods7902700000Other Expenses1860100000Sugar4222700000Bio Fuels & Spirits830200000Country Liquor2938600000Sugar13597200000Bio Fuels & Spirits3062200000Country Liquor87663000007991500000254257000004789000001827500000751260000023598200000Sugar469000000Bio Fuels & Spirits26200000Country Liquor46800000Sugar400000000Bio Fuels & Spirits-11700000Country Liquor137100000542000000525400000106000000465100000179200000367100000256800000-306800000Sugar14277800000Bio Fuels & Spirits3385100000Country Liquor63290000018295800000145890000019754700000Sugar2304500000Bio Fuels & Spirits208800000Country Liquor100200000261350000073680000009981500000Remeasurement benefits (losses) on defined benefit obligation-21800000-21800000Remeasurement benefits (losses) on defined benefit obligation-21800000-21800000-5500000-5500000Foreign Currency Translation Reserve33000003300000Foreign Currency Translation Reserve125000001250000000-13000000-3800000